Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Jan;1(1):93-96.
doi: 10.3892/etm_00000017. Epub 2010 Jan 1.

Human MLH1 status can potentially predict cisplatin sensitivity but not microsatellite instability in head and neck squamous cell carcinoma cells

Affiliations

Human MLH1 status can potentially predict cisplatin sensitivity but not microsatellite instability in head and neck squamous cell carcinoma cells

Makoto Adachi et al. Exp Ther Med. 2010 Jan.

Abstract

Resistance to platinum-based chemotherapy frequently poses a serious problem in the treatment of head and neck squamous cell carcinoma. In this study, we isolated cisplatin-resistant cells from a head and neck squamous cell carcinoma cell line. The mismatch repair (MMR) system is known as one of the cisplatin-resistant mechanisms. When the expression levels of hMLH1 and hMSH2, a mismatch repair gene and its gene product, were analyzed, the hMLH1 mRNA and protein expression levels were significantly decreased in the cisplatin-resistant cell lines compared with a cisplatin-sensitive cell line. In addition, the microsatellite instability (MSI) phenotype was examined for the absence of MMR. Our data support the hypothesis that hMLH1 mRNA and protein expression levels are predictors of cisplatin sensitivity, but MSI was not involved in cisplatin resistance. The status of hMLH1 predicts the sensitivity of head and neck squamous cell carcinoma to platinum-based chemotherapy.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Sensitivities of head and neck squamous cell carcinoma and resistant cell lines to cisplatin. UM-SCC 23, UM-SCC 81B and UM-SCC 23 C/R cells were treated with cisplatin for 24 h, and the cytotoxicity was analyzed using a colony-formation assay. Each data point is the mean of three independent experiments. Vertical bars represent standard deviations.
Figure 2.
Figure 2.
mRNA expression levels of hMLH1 and hMSH2. UM-SCC 23, UM-SCC 81B and UM-SCC 23 C/R cells were analyzed using real-time RT-PCR. Each data point is the mean of three independent experiments. Vertical bars represent standard deviations.
Figure 3.
Figure 3.
Expression levels of hMLH1 and hMSH2 mismatch repair proteins. UM-SCC 23, UM-SCC 81B and UM-SCC 23 C/R cells were examined by Western blot analysis.
Figure 4.
Figure 4.
Changes in the microsatellite sequence. Microsatellite sequence changes were detected with Gene Scan. Results in D9S171 for UM-SCC 81B are shown. The upper column shows results noted in 59 of 61 samples, the lower column shows microsatellite sequence changes in 2 of 61 samples. The red lines indicate base size marker and the black lines indicate the samples. The arrow shows 100 bases.

Similar articles

Cited by

References

    1. Choong N, Vokes E. Expanding role of the medical oncologist in the management of head and neck cancer. CA Cancer J Clin. 2008;58:32–53. - PubMed
    1. Wozniak K, Blasiak J. Recognition and repair of DNA-cisplatin adducts. Acta Biochim Pol. 2002;49:583–596. - PubMed
    1. Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene. 2003;22:7265–7279. - PubMed
    1. Yang Z, Faustino PJ, Andrews PA, Monastra R, Rasmussen AA, Ellison CD, Cullen KJ. Decreased cisplatin/DNA adduct formation is associated with cisplatin resistance in human head and neck cancer cell lines. Cancer Chemother Pharmacol. 2000;46:255–262. - PubMed
    1. Papouli E, Cejka P, Jiricny J. Dependence of the cytotoxicity of DNA-damaging agents on the mismatch repair status of human cells. Cancer Res. 2004;64:3391–3394. - PubMed

LinkOut - more resources